Orders are packed in insulated Cool Shield mailers to help protect stability in transit, and orders over $100 qualify for free shipping
1 = 50mcg (25mcg BPC-157 25mcg TB-500)
Cagrilintide + Tirzepatide Clinical Evidence Context Direct stack evidence No published human trial has tested cagrilintide + tirzepatide together
A parallel line of work by Chang and colleagues (J Appl Physiol, 2011) examined cultured rat Achilles tendon fibroblasts and reported increased outgrowth, survival and migration alongside elevated phosphorylation of focal adhesion kinase (FAK) and paxillin, the adaptor pair coupling integrin engagement to cytoskeletal reorganisation
One person with IBS reported that ten days of oral BPC157 calmed the cramps Id battled for years. Another poster claims fewer colds since starting, hinting at possible BPC157 immune system support
Reasonable candidates include: Mild to moderate IBD as an adjunct (never as sole therapy, always with GI oversight) IBS with a documented inflammatory component Post-infectious gut dysfunction where both tissue damage and persistent low-grade inflammation are present Mixed presentations, heartburn plus intestinal sensitivity plus food reactivity, where the clinical picture suggests multiple mechanisms Where this falls apart is when people treat it as a silver bullet